+

PE20100742A1 - Nuevos procedimientos y formulaciones - Google Patents

Nuevos procedimientos y formulaciones

Info

Publication number
PE20100742A1
PE20100742A1 PE2010000446A PE2010000446A PE20100742A1 PE 20100742 A1 PE20100742 A1 PE 20100742A1 PE 2010000446 A PE2010000446 A PE 2010000446A PE 2010000446 A PE2010000446 A PE 2010000446A PE 20100742 A1 PE20100742 A1 PE 20100742A1
Authority
PE
Peru
Prior art keywords
mannitol
sorbitol
lactose
cellulose
weight
Prior art date
Application number
PE2010000446A
Other languages
English (en)
Inventor
Khalil As'ad Abu
John Robert George Appleby
Philip Blatcher
Lesley Anne Humphries
Jiri Kasparec
Richard S Lloyd
Paul G Spoors
Lois E Vernon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38049392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20100742A1 publication Critical patent/PE20100742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION MANTENIDA QUE COMPRENDE: A) 8-(2,6-DIFLOROFENIL)-4-(4-FLUORO-2-METILFENIL)-2-{[2-HIDROXI-1-(HIDROXIMETIL)ETIL]AMINO}PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONA EN UNA PROPORCION 2,5% EN PESO; B) 10 A 70% EN PESO DE POLIMERO RETARDADOR DE LA LIBRACION SELECCIONADOS ENTRE METILCELULOSA SODICA, HIDROXIPROPIL-CELULOSA, CARBOXIMETILAMIDA, ENTRE OTROS; C) DILUYENTES SELECCIONADOS ENTRE LACTOSA, MANITOL, SORBITOL, ALMIDON, ENTRE OTROS; D) ADYUVANTE DE COMPRESION SELECCIONADO ENTRE CELULOSA MICRCRISTALINA, FOSFATO CALCICO, MANITOL, LACTOSA O SORBITOL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR CINASA p38
PE2010000446A 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones PE20100742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73667905P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
PE20100742A1 true PE20100742A1 (es) 2010-11-25

Family

ID=38049392

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2006001434A PE20070823A1 (es) 2005-11-15 2006-11-13 Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
PE2010000447A PE20100743A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones
PE2010000446A PE20100742A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2006001434A PE20070823A1 (es) 2005-11-15 2006-11-13 Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
PE2010000447A PE20100743A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones

Country Status (18)

Country Link
US (1) US20080268044A1 (es)
EP (1) EP1954282A4 (es)
JP (1) JP2009516000A (es)
KR (1) KR20080074178A (es)
CN (3) CN102030749A (es)
AR (1) AR056218A1 (es)
AU (1) AU2006315162A1 (es)
BR (1) BRPI0618581A2 (es)
CA (1) CA2629912A1 (es)
CR (1) CR9992A (es)
EA (1) EA200801327A1 (es)
IL (1) IL191482A0 (es)
MA (1) MA29949B1 (es)
NO (1) NO20082541L (es)
PE (3) PE20070823A1 (es)
TW (1) TW200738243A (es)
WO (1) WO2007059500A2 (es)
ZA (1) ZA200803987B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524806A (en) 2000-10-23 2006-03-31 Smithkline Beecham Corp Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
TWI389690B (zh) * 2005-03-25 2013-03-21 Glaxo Group Ltd 新穎化合物（一）
EP2032142A4 (en) * 2006-06-16 2010-07-21 Glaxo Group Ltd NOVEL CONNECTIONS
EP3669878A1 (en) 2006-08-10 2020-06-24 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US9180198B2 (en) 2009-09-23 2015-11-10 Korea United Pharm, Inc. Slow-release cilostazol tablet having an improved elution rate and minimal side effects
US20120225105A1 (en) * 2010-10-01 2012-09-06 James Swanzy Sugar-based dispersion
EP2968173B1 (en) 2013-03-14 2020-10-14 Amgen Inc. Heterocyclic compounds and their uses
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
KR20180044256A (ko) 2015-06-10 2018-05-02 엑소반트 사이언시즈 게엠베하 A7-니코틴성 아세틸콜린 수용체의 작용제로서의 아미노벤즈이소옥사졸 화합물
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
SG11202003035SA (en) 2017-10-05 2020-04-29 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
EP1161942A3 (en) * 1998-01-30 2003-12-10 R-Tech Ueno, Ltd. Ophthalmic composition
NZ524806A (en) * 2000-10-23 2006-03-31 Smithkline Beecham Corp Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL
MXPA04002762A (es) * 2001-09-25 2004-06-29 Pharmacia Corp Formas de estado solido de n-(2 -hidroxiacetil) -5-(4-piperidil) -4-(4-pirimidinil) -3-(4-clorofenil) pirazol.

Also Published As

Publication number Publication date
EA200801327A1 (ru) 2009-02-27
MA29949B1 (fr) 2008-11-03
CR9992A (es) 2008-07-29
AU2006315162A1 (en) 2007-05-24
JP2009516000A (ja) 2009-04-16
KR20080074178A (ko) 2008-08-12
TW200738243A (en) 2007-10-16
WO2007059500A2 (en) 2007-05-24
PE20100743A1 (es) 2010-11-25
NO20082541L (no) 2008-08-14
CN101360497A (zh) 2009-02-04
US20080268044A1 (en) 2008-10-30
EP1954282A4 (en) 2011-10-12
WO2007059500A3 (en) 2007-11-22
CA2629912A1 (en) 2007-05-24
PE20070823A1 (es) 2007-08-09
EP1954282A2 (en) 2008-08-13
BRPI0618581A2 (pt) 2011-09-06
IL191482A0 (en) 2009-02-11
CN102030749A (zh) 2011-04-27
ZA200803987B (en) 2009-12-30
CN102030748A (zh) 2011-04-27
AR056218A1 (es) 2007-09-26

Similar Documents

Publication Publication Date Title
PE20100742A1 (es) Nuevos procedimientos y formulaciones
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
ECSP055524A (es) Derivados de indolin-fenilsufonamida
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
MY135902A (en) SUBSTITUTED HEXAHYDROPYRAZINO [1, 2-a] PYRIMIDINE-4, 7-DIONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
DOP2002000429A (es) Imidazotriazinas
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
TW200510417A (en) Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
DOP2006000082A (es) Forma cristalina ortorrómbicadel maleato de asenapina y su uso enel tratamiento de trastornos mentales.
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
JO2787B1 (en) Alternative amide derivatives and methods of use
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
PT2432760E (pt) Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载